The MarketWatch News Department was not involved in the creation of this content. Cure HHT plays pivotal role in the NIH-sponsored PATH Trial becoming the first successful, large-scale randomized ...
A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
Please provide your email address to receive an email when new articles are posted on . A multicenter research effort yielded findings that may allow for more effective and personalized treatment of ...
MONKTON, MD, UNITED STATES, March 25, 2026 /EINPresswire.com/ — Cure HHT proudly announces the publication of “Clinical Spectrum of Hereditary Hemorrhagic ...
Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated IDA management, this series of Ace the Case sessions will highlight key teaching points ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results